Eligibility criteria in haematological cancer clinical trials-what's needed?
Lancet Haematol
.
2020 Jan;7(1):e10.
doi: 10.1016/S2352-3026(19)30160-7.
Epub 2019 Dec 5.
Authors
Mattia Calissano
1
,
Maria Beatrice Panico
2
,
Daniel J O'Connor
3
Affiliations
1
Vigilance and Risk Management of Medicines, Medicines and Healthcare products Regulatory Agency, London E14 4PU, UK.
2
Clinical Trials Unit, Medicines and Healthcare products Regulatory Agency, London E14 4PU, UK.
3
Licencing Division, Medicines and Healthcare products Regulatory Agency, London E14 4PU, UK. Electronic address: daniel.oconnor@mhra.gov.uk.
PMID:
31813851
DOI:
10.1016/S2352-3026(19)30160-7
No abstract available
Publication types
Letter
Comment
MeSH terms
Hematologic Neoplasms*
Humans